Severe acute respiratory syndrome: Difference between revisions
Jump to navigation
Jump to search
| Line 33: | Line 33: | ||
==Treatment== | ==Treatment== | ||
[[Severe acute respiratory syndrome medical therapy|Medical Therapy]] | [[Severe acute respiratory syndrome surgery |Surgery]] | [[Severe acute respiratory syndrome primary prevention|Primary Prevention]] | [[Severe acute respiratory syndrome secondary prevention|Secondary Prevention]] | [[Severe acute respiratory syndrome cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Severe acute respiratory syndrome future or investigational therapies|Future or Investigational Therapies]] | [[Severe acute respiratory syndrome social impact|Social Impact]] | [[Severe acute respiratory syndrome medical therapy|Medical Therapy]] | [[Severe acute respiratory syndrome surgery |Surgery]] | [[Severe acute respiratory syndrome primary prevention|Primary Prevention]] | [[Severe acute respiratory syndrome secondary prevention|Secondary Prevention]] | [[Severe acute respiratory syndrome cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Severe acute respiratory syndrome future or investigational therapies|Future or Investigational Therapies]] | [[Severe acute respiratory syndrome social impact|Social Impact]] | ||
* '''Severe acute respiratory distress syndrome- coronavirus'''<ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy 2014 | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2014 | isbn = 978-1930808782 }}</ref><ref name="pmid16968120">{{cite journal| author=Stockman LJ, Bellamy R, Garner P| title=SARS: systematic review of treatment effects. | journal=PLoS Med | year= 2006 | volume= 3 | issue= 9 | pages= e343 | pmid=16968120 | doi=10.1371/journal.pmed.0030343 | pmc=PMC1564166 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16968120 }} </ref><ref name="pmid15766649">{{cite journal| author=Groneberg DA, Poutanen SM, Low DE, Lode H, Welte T, Zabel P| title=Treatment and vaccines for severe acute respiratory syndrome. | journal=Lancet Infect Dis | year= 2005 | volume= 5 | issue= 3 | pages= 147-55 | pmid=15766649 | doi=10.1016/S1473-3099(05)01307-1 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15766649 }} </ref> | |||
:* Preferred regimen: supportive therapy | |||
:* Note: New therapies were studied for SARS during the last outbreaks which concluded | |||
::* [[Ribavirin]] ineffective and probably harmful due to haemolytic anaemia. | |||
::* [[Lopinavir]] {{and}} [[Ritonavir]] is still controversial and need further investigation. | |||
::* Interferon has no benefit and its studies are inconclusive. | |||
::* [[Corticosteroids]] increases risk of fungal infections, some studies showed a higher incidence of psychosis, diabetes, avascular necrosis and osteoporosis. | |||
::* Inhaled [[Nitric oxide]] potent mediator of airway inflammation, its has improved oxygenation in some studies. | |||
==Case Studies== | ==Case Studies== | ||
Revision as of 18:22, 29 July 2015
| Severe acute respiratory syndrome | |
 | |
|---|---|
| SARS Virus Particle |
|
Severe Acute Respiratory Syndrome Microchapters |
|
Differentiating Severe Acute Respiratory Syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Severe acute respiratory syndrome On the Web |
|
American Roentgen Ray Society Images of Severe acute respiratory syndrome |
|
Directions to Hospitals Treating Severe acute respiratory syndrome |
|
Risk calculators and risk factors for Severe acute respiratory syndrome |
For patient information click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Synonyms and keywords: SARS; SARS associated
Overview
Historical Perspective
Pathophysiology
Differentiating Severe Acute Respiratory Syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria | History and Symptoms | Physical Examination | Laboratory Findings | Chest X Ray | Other Imaging Findings | Other Diagnostic Studies
Treatment
Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies | Social Impact
- Preferred regimen: supportive therapy
- Note: New therapies were studied for SARS during the last outbreaks which concluded
- Ribavirin ineffective and probably harmful due to haemolytic anaemia.
- Lopinavir AND Ritonavir is still controversial and need further investigation.
- Interferon has no benefit and its studies are inconclusive.
- Corticosteroids increases risk of fungal infections, some studies showed a higher incidence of psychosis, diabetes, avascular necrosis and osteoporosis.
- Inhaled Nitric oxide potent mediator of airway inflammation, its has improved oxygenation in some studies.
Case Studies
External Links
- Official SARS information from the World Health Organization
- Official SARS information from the United States Centers for Disease Control
- NIOSH Topic Area: Severe Acute Respiratory Syndrome (SARS)
- NIOSH Publication: Understanding Respiratory Protection Against SARS
Template:Baltimore classification Template:Viral diseases
Template:Respiratory pathology
- ↑ Gilbert, David (2014). The Sanford guide to antimicrobial therapy 2014. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808782.
- ↑ Stockman LJ, Bellamy R, Garner P (2006). "SARS: systematic review of treatment effects". PLoS Med. 3 (9): e343. doi:10.1371/journal.pmed.0030343. PMC 1564166. PMID 16968120.
- ↑ Groneberg DA, Poutanen SM, Low DE, Lode H, Welte T, Zabel P (2005). "Treatment and vaccines for severe acute respiratory syndrome". Lancet Infect Dis. 5 (3): 147–55. doi:10.1016/S1473-3099(05)01307-1. PMID 15766649.